Valuation: Lundbeck

Market Cap 39.94B 6.17B 5.34B 4.96B 4.58B 8.65B 587B 8.75B 58.47B 22.96B 294B 23.19B 22.68B 973B P/E 2026 *
9.07x
P/E 2027 * 9.09x
Enterprise Value 44.02B 6.8B 5.88B 5.47B 5.05B 9.53B 647B 9.64B 64.44B 25.3B 324B 25.56B 24.99B 1,072B EV / Sales 2026 *
1.7x
EV / Sales 2027 * 1.54x
Free-Float
30.75%
Yield 2026 *
3.62%
Yield 2027 * 3.67%
1 day+0.42%
1 week-2.46%
Current month-0.94%
1 month-3.55%
3 months+2.81%
6 months-2.36%
Current year-1.55%
1 week 4.72
Extreme 4.72
4.88
1 month 4.72
Extreme 4.72
4.96
Current year 4.22
Extreme 4.22
5.32
1 year 3.86
Extreme 3.865
5.32
3 years 3.12
Extreme 3.125
5.57
5 years 3.03
Extreme 3.028
10.99
10 years 3.03
Extreme 3.028
10.99
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 66 24/03/2015
Director/Board Member 60 19/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-2.46% - - 6.03B
+5.64%-1.38%+23.39%+107.99% 97.22B
+2.43%+2.89%+50.82%+162.17% 54.7B
+0.34%+2.76%+3.83%+282.05% 24.02B
-1.02%+0.06%-14.23%-17.62% 8.27B
-2.00%-3.42%-36.20%-32.35% 7.4B
-0.52%+0.06%-7.70%-29.84% 6.9B
+0.06%-3.75%-2.87%+23.13% 5.21B
-2.96%-2.19%-9.58%-8.39% 3.74B
-1.93%-8.65%+8.06%+16.53% 3.59B
Average +0.05%-2.85%+1.73%+55.96% 23.45B
Weighted average by Cap. +2.98%-3.20%+22.20%+121.78%

Financials

2026 *2027 *
Net sales 25.83B 3.99B 3.45B 3.21B 2.96B 5.59B 380B 5.65B 37.81B 14.84B 190B 14.99B 14.66B 629B 25.85B 4B 3.45B 3.21B 2.97B 5.6B 380B 5.66B 37.84B 14.86B 190B 15.01B 14.68B 630B
Net income 4.56B 705M 609M 567M 523M 987M 67.05B 998M 6.68B 2.62B 33.57B 2.65B 2.59B 111B 4.57B 706M 610M 567M 524M 989M 67.16B 1B 6.69B 2.63B 33.63B 2.65B 2.59B 111B
Net Debt 4.08B 630M 545M 507M 468M 883M 59.95B 893M 5.97B 2.34B 30.02B 2.37B 2.32B 99.34B -9.63M -1.49M -1.29M -1.2M -1.11M -2.09M -142M -2.11M -14.1M -5.54M -70.93M -5.59M -5.47M -235M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
05/08/26 €4.750 -0.11%
04/08/26 €4.755 +0.42%
03/08/26 €4.735 -1.35%
31/07/26 €4.800 -0.41%
30/07/26 €4.820 -0.82%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
41.50DKK
Average target price
47.88DKK
Spread / Average Target
+15.36%

Quarterly revenue - Rate of surprise